Literature DB >> 10392494

Diffuse brain stem glioma. A review of stereotactic biopsies.

M Cartmill1, J Punt.   

Abstract

The diagnosis and management of diffuse brain stem gliomas (DBSGs) remain a challenging problem for the neurosurgeon and neuro-oncologist. Opposing views on the necessity for biopsy have emerged over the last decade. Open biopsy, with its prohibitive morbidity and mortality, has been replaced by stereotactically guided biopsy, with markedly reduced risk. This has been paralleled by improvements in imaging techniques and diagnostic accuracy, which has created reluctance to endorse diagnostic biopsies coupled with the potential of nonrepresentative samples from a heterogeneous tumour mass. For typical DBSGs biopsy is now accepted as unnecessary. We performed a retrospective analysis of radiologically and histologically proven DBSGs in 18 children to assess both morbidity and reliability of our stereotactically guided biopsy procedure.

Entities:  

Mesh:

Year:  1999        PMID: 10392494     DOI: 10.1007/s003810050379

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  31 in total

1.  Pre-irradiation intensive induction and marrow-ablative consolidation chemotherapy in young children with newly diagnosed high-grade brainstem gliomas: report of the "head-start" I and II clinical trials.

Authors:  Diana S Osorio; Neha Patel; Lingyun Ji; Richard Sposto; Joseph Stanek; Sharon L Gardner; Jeffrey C Allen; Albert Cornelius; Geoffrey B McCowage; Amanda Termuhlen; Ira J Dunkel; Melanie Comito; James Garvin; Jonathan L Finlay
Journal:  J Neurooncol       Date:  2018-11-03       Impact factor: 4.130

2.  Post mortem examinations in diffuse intrinsic pontine glioma: challenges and chances.

Authors:  Paola Angelini; Cynthia Hawkins; Normand Laperriere; Eric Bouffet; Ute Bartels
Journal:  J Neurooncol       Date:  2010-05-16       Impact factor: 4.130

3.  Stereotactic biopsy of brainstem lesions: 21 years experiences of a single center.

Authors:  Johanna Quick-Weller; Stephanie Lescher; Markus Bruder; Nazife Dinc; Bedjan Behmanesh; Volker Seifert; Lutz Weise; Gerhard Marquardt
Journal:  J Neurooncol       Date:  2016-06-13       Impact factor: 4.130

4.  Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group.

Authors:  Kenneth J Cohen; Richard L Heideman; Tianni Zhou; Emiko J Holmes; Robert S Lavey; Eric Bouffet; Ian F Pollack
Journal:  Neuro Oncol       Date:  2011-02-22       Impact factor: 12.300

5.  DTI fusion with conventional MR imaging in intra-operative MRI suite for paediatric brainstem glioma biopsy.

Authors:  Sharon Y Y Low; Shui Yen Soh; Min Wei Chen; Lee Ping Ng; David C Y Low; Wan Tew Seow
Journal:  Childs Nerv Syst       Date:  2017-10-24       Impact factor: 1.475

6.  Frameless stereotactic procedures in pediatric patients: safety and diagnostic efficacy.

Authors:  Mary G Parreño; Xiao Bo; Okezie O Kanu; Shlomi Constantini; Andrew A Kanner
Journal:  Childs Nerv Syst       Date:  2011-06-10       Impact factor: 1.475

7.  Use of intra-operative stimulation of brainstem lesion target sites for frameless stereotactic biopsies.

Authors:  Jason Labuschagne; Denis Mutyaba; Jacques Nel; Claudia Casieri
Journal:  Childs Nerv Syst       Date:  2021-03-08       Impact factor: 1.475

8.  B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.

Authors:  Zhiping Zhou; Neal Luther; George M Ibrahim; Cynthia Hawkins; Rajeev Vibhakar; Michael H Handler; Mark M Souweidane
Journal:  J Neurooncol       Date:  2012-12-12       Impact factor: 4.130

9.  Outcome and prognostic factors of childhood diffuse brainstem glioma.

Authors:  Semie Hong; Il Han Kim; Kyu Chang Wang
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

10.  The efficacy of a biopsy of intrinsic brainstem lesions for decision making of the treatments.

Authors:  Hideki Ogiwara; Nobuhito Morota
Journal:  Childs Nerv Syst       Date:  2013-02-03       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.